<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01537692</url>
  </required_header>
  <id_info>
    <org_study_id>BDP-AR-101</org_study_id>
    <nct_id>NCT01537692</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Pharmacokinetics and Safety of BDP HFA Nasal Aerosol</brief_title>
  <official_title>A Randomized, Open-Label, 3-Period Crossover Study to Investigate the Pharmacokinetics, Safety and Tolerability of BDP HFA Nasal Aerosol in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the systemic levels of beclomethasone 17
      monopropionate (17 BMP - the active metabolite of BDP) after intranasal administration of BDP
      HFA with the systemic levels of 17 BMP after administration of orally inhaled BDP HFA in
      healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>24 hours post dose</time_frame>
    <description>Area under the plasma concentration time curve until the last measurable value (AUClast) for 17-BMP
Maximum plasma concentration (Cmax) for 17-BMP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>24 hours post dose</time_frame>
    <description>Area under the plasma concentration time curve extrapolated to infinity (AUC0-inf), time to mean peak plasma concentration (Tmax), and the terminal elimination half-life (t1/2) for 17-BMP
AUClast, AUC0-inf, Cmax, Tmax, t1/2 for BDP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of BDP HFA nasal aerosol</measure>
    <time_frame>24 hours post dose</time_frame>
    <description>Change from baseline in safety and tolerability endpoints - including Adverse events, changes in vital signs (blood pressure and pulse rate) and ENT exams (every visit) and safety laboratory assessments and physical exams (end of study)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>BDP HFA Nasal Aerosol 80 mcg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose, intranasal aerosol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BDP HFA Nasal Aerosol 320 mcg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose, intranasal aerosol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BDP HFA Inhalation Aerosol 320 mcg/d</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose, orally inhaled aerosol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDP HFA Nasal Aerosol</intervention_name>
    <description>BDP HFA Nasal 80mcg</description>
    <arm_group_label>BDP HFA Nasal Aerosol 80 mcg/d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDP HFA Nasal Aerosol</intervention_name>
    <description>BDP HFA Nasal 320mcg</description>
    <arm_group_label>BDP HFA Nasal Aerosol 320 mcg/d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDP HFA Inhalation Aerosol (QVAR)</intervention_name>
    <description>BDP HFA Oral 320mcg</description>
    <arm_group_label>BDP HFA Inhalation Aerosol 320 mcg/d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed Consent

          -  Male or female subjects 18-45 years of age

          -  General good health

        Exclusion Criteria:

          -  History of physical findings of nasal pathology (within 60 days prior to Screening
             Visit)

          -  Participation in any investigational drug study 30 days preceding Screening Visit

          -  History of respiratory infection/disorder with 28 days preceding Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudeesh Tantry, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Teva Global Respiratory Research</affiliation>
  </overall_official>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2012</study_first_submitted>
  <study_first_submitted_qc>February 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2012</study_first_posted>
  <last_update_submitted>February 22, 2012</last_update_submitted>
  <last_update_submitted_qc>February 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

